Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biovie Inc (NQ: BIVI )

15.03 -0.04 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,364
Open 15.27
Bid (Size) 14.94 (1)
Ask (Size) 15.03 (1)
Prev. Close 15.07
Today's Range 14.90 - 15.71
52wk Range 7.500 - 46.10
Shares Outstanding 13,958,516
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
NE3107 Is the First Potentially Disease Modifying, Anti-Inflammatory Insulin Sensitizer Therapy In A Pivotal Phase 3 Trial 
From GlobeNewswire News Releases
BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
Trial will be first Phase 3 disease modifying anti-inflammatory insulin sensitizer therapy in Alzheimer’s disease 
From GlobeNewswire News Releases

Performance

YTD
-14.55%
-14.55%
1 Month
-11.59%
-11.59%
3 Month
-30.09%
-30.09%
6 Month
-59.93%
-59.93%
1 Year
+50.45%
+50.45%

More News

Read More
Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
From GlobeNewswire News Releases
Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association
From GlobeNewswire News Releases
BioVie Added to Russell Microcap® Index
From GlobeNewswire News Releases
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
From GlobeNewswire News Releases
BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
From GlobeNewswire News Releases
BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI
From GlobeNewswire News Releases
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
From GlobeNewswire News Releases
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
From GlobeNewswire News Releases
BioVie Hosting Research & Development Day
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]